BRPI1014631A2 - peptídeos e seus usos. - Google Patents

peptídeos e seus usos.

Info

Publication number
BRPI1014631A2
BRPI1014631A2 BRPI1014631-8A BRPI1014631A BRPI1014631A2 BR PI1014631 A2 BRPI1014631 A2 BR PI1014631A2 BR PI1014631 A BRPI1014631 A BR PI1014631A BR PI1014631 A2 BRPI1014631 A2 BR PI1014631A2
Authority
BR
Brazil
Prior art keywords
treating
variant
effective
peptides
present
Prior art date
Application number
BRPI1014631-8A
Other languages
English (en)
Inventor
Jin Kim Hae
Joung Moon Eun
Seon Kim Yang
Joon Kwon Young
Original Assignee
Ensoltek Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ensoltek Co., Ltd filed Critical Ensoltek Co., Ltd
Publication of BRPI1014631A2 publication Critical patent/BRPI1014631A2/pt
Publication of BRPI1014631B1 publication Critical patent/BRPI1014631B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

peptídeos e seus usos a presente invenção oferece um peptídeo compreendendo uma sequência de aminoácidos de seq lo no: 1, um variante e um sal farmaceuticamente aceitável. um novo peptídeo da presente invenção, variante do mesmo e seu sal são eficazes no tratamento e/ou prevenção de doenças discais degenerativas, no tratamento da fibrose em órgãos corporais, no tratamento do câncer e/ou glomerulosclerose, e são eficazes na inibição do sinal tgf-beta 1 .
BRPI1014631-8A 2009-08-14 2010-02-12 Composições que compreendem um peptídeo que inibe a sinalização de tgf-beta 1 em um veículo farmaceuticamente aceitável e usos do dito peptídeo para tratar ou prevenir doenças discais degenerativas, fibrose em órgãos corporais, câncer e glomerulosclerose BRPI1014631B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0075142 2009-08-14
KR1020090075142A KR100983182B1 (ko) 2009-08-14 2009-08-14 신규 펩타이드 및 그 용도
PCT/KR2010/000907 WO2011019123A1 (en) 2009-08-14 2010-02-12 Novel peptide and use thereof

Publications (2)

Publication Number Publication Date
BRPI1014631A2 true BRPI1014631A2 (pt) 2019-04-16
BRPI1014631B1 BRPI1014631B1 (pt) 2022-01-18

Family

ID=43010309

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014631-8A BRPI1014631B1 (pt) 2009-08-14 2010-02-12 Composições que compreendem um peptídeo que inibe a sinalização de tgf-beta 1 em um veículo farmaceuticamente aceitável e usos do dito peptídeo para tratar ou prevenir doenças discais degenerativas, fibrose em órgãos corporais, câncer e glomerulosclerose

Country Status (15)

Country Link
US (1) US8691749B2 (pt)
EP (1) EP2464656B1 (pt)
JP (1) JP5475131B2 (pt)
KR (1) KR100983182B1 (pt)
CN (1) CN102482323B (pt)
AU (1) AU2010283169C1 (pt)
BR (1) BRPI1014631B1 (pt)
CA (1) CA2770018C (pt)
ES (1) ES2548527T3 (pt)
HK (1) HK1168363A1 (pt)
MX (1) MX2011013972A (pt)
PL (1) PL2464656T3 (pt)
RU (1) RU2498992C1 (pt)
SG (1) SG178260A1 (pt)
WO (1) WO2011019123A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101434465B1 (ko) 2012-07-16 2014-08-26 조선대학교산학협력단 바실러스 아밀로리쿼파시엔스 eml-cap3으로부터 분리된 신규한 항균 및 항진균 펩타이드 및 이의 용도
KR101995768B1 (ko) * 2019-03-13 2019-07-03 (주)엔솔바이오사이언스 신규 펩타이드 및 그 용도
CN110613837A (zh) * 2019-10-24 2019-12-27 内蒙古医科大学第二附属医院 TGF-β在制备预防或治疗腰椎间盘突出药物中的应用
KR20230167231A (ko) 2022-05-31 2023-12-08 주식회사 엔솔바이오사이언스 염형태 변형 펩타이드의 제조방법 및 그를 이용하여 제조된 펩타이드
KR20240000395A (ko) * 2022-06-22 2024-01-02 주식회사 유씨아이테라퓨틱스 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도
WO2024101942A1 (ko) * 2022-11-11 2024-05-16 주식회사 유씨아이테라퓨틱스 유전자 조작된 세포 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US6509314B1 (en) * 1988-06-28 2003-01-21 The Burnham Institute Methods of preventing or reducing scarring with decorin or biglycan
AU673506B2 (en) * 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
CA2455884C (en) * 2001-08-15 2015-09-22 Justin R. Fallon Treatment of muscular dystrophies and related disorders
EP1485116A4 (en) * 2002-02-27 2006-06-07 Univ Wake Forest ANGIOTENSIN- (1-7) AND AGONISTS OF ANGIOTENSIN- (1-7) FOR THE INHIBITION OF GROWTH OF CANCER CELLS
WO2006017456A2 (en) * 2004-08-04 2006-02-16 Mcdermott Daniel J Chymopapain isoenzymes, compositions, and uses thereof
US20100143949A1 (en) 2006-10-31 2010-06-10 George Mason Intellectual Properties, Inc. Biomarkers for colorectal cancer
US20100190686A1 (en) * 2007-06-22 2010-07-29 The University Of Georgia Research Foundation Novel secreted proteins of adipocytes for diagnostic purposes

Also Published As

Publication number Publication date
RU2012108179A (ru) 2013-09-20
RU2498992C1 (ru) 2013-11-20
MX2011013972A (es) 2012-04-02
KR100983182B1 (ko) 2010-09-20
WO2011019123A1 (en) 2011-02-17
ES2548527T3 (es) 2015-10-19
AU2010283169C1 (en) 2016-03-03
US20120190625A1 (en) 2012-07-26
AU2010283169B2 (en) 2015-11-12
BRPI1014631B1 (pt) 2022-01-18
SG178260A1 (en) 2012-03-29
CA2770018A1 (en) 2011-02-17
EP2464656A1 (en) 2012-06-20
AU2010283169A1 (en) 2012-03-29
JP2013501711A (ja) 2013-01-17
CN102482323A (zh) 2012-05-30
JP5475131B2 (ja) 2014-04-16
EP2464656B1 (en) 2015-07-01
PL2464656T3 (pl) 2015-12-31
HK1168363A1 (en) 2012-12-28
US8691749B2 (en) 2014-04-08
CN102482323B (zh) 2014-05-14
EP2464656A4 (en) 2013-06-12
CA2770018C (en) 2015-11-24

Similar Documents

Publication Publication Date Title
IL262976A (en) Chimeric proteins Enzyme medical lysosomes are designated and their uses
BRPI1014631A2 (pt) peptídeos e seus usos.
JP2012176978A5 (pt)
IN2012DN02981A (pt)
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
EP2808029A3 (en) Combination therapies using cyclosporine and aromatic cationic peptides
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2013080147A3 (en) Anticancer fusion protein
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
NZ608502A (en) Polypeptides that bind to human complement component c5
JP2015510393A5 (pt)
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
GB201018518D0 (en) Novel endolysin
ES2656562T3 (es) Derivado de polimixina y usos del mismo
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
JP2006506942A5 (pt)
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
NZ610620A (en) Inhibitors of apoptosis and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.